Press Release: Novartis Pluvicto(TM) demonstrates -2-

Novartis

98.80 EUR -0.40%

• Charts
• News
• Analysen

Kaufen Verkaufen

References

1. Data on file.

2. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator

Applications USA, Inc.; 2025.

3. An International Prospective Open-label, Randomized, Phase III Study

Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in

Adult Male Patients With mHSPC (PSMAddition). ClinicalTrials.gov

identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025.

https://clinicaltrials.gov/study/NCT04720157.

4. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive

prostate cancer--upfront triplet versus doublet combination therapy. ESMO

Open 2023l doi: 10.1016/j.esmoop.2023.101194

5. Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177--PSMA-617 for

Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi:

10.1056/NEJMoa2107322.

6. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change

of androgen receptor pathway inhibitor therapy for taxane-naive patients

with progressive metastatic castration-resistant prostate cancer

(PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024;

doi: 10.1016/S0140-6736(24)01653-2.

7. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate

Cancer (Pluvicto). Accessed June 18, 2024.

https://www.uchicagomedicine.org/cancer/types-treatments/prostate-cancer/treatment/lutetium-177-psma-therapy-for-prostate-cancer.

8. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision

Cancer Treatment [published correction appears in AJR Am J Roentgenol.

2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol.

2017;209(2):277-288. doi:10.2214/AJR.17.18264

9. Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In:

Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical

Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

June 02, 2025 01:15 ET (05:15 GMT)